AI-generated research brief — verify at source
Novel Three-Component DTcP Vaccine Meets Non-Inferiority and Superiority Thresholds Against Licensed Comparator
A phase III randomised trial in China found that both primary schedules of the novel genetically engineered three-component acellular pertussis vaccine (DTcP) achieved non-inferior safety profiles and superior or non-inferior immunogenicity against all pertussis antigens compared with the licensed DTaP-IPV-Hib (Pentaxim) control. The results support DTcP as a potentially viable domestically produced alternative at a time when pertussis resurgence is accelerating in China.
What Was Studied
This trial evaluated whether a novel diphtheria, tetanus, and three-component acellular pertussis combination vaccine (DTcP) — China’s first genetically engineered pertussis vaccine incorporating pertussis toxoid, filamentous hemagglutinin, and pertactin — could match or surpass the safety and immunogenicity of an established licensed pentavalent comparator when administered under two different infant primary series schedules. The research was motivated by waning immunity associated with acellular pertussis vaccines and a post-COVID-19 resurgence in pertussis cases across China.
How It Was Studied
This was a randomised, blinded, controlled phase III clinical trial enrolling 1,380 healthy 2-month-old infants from Henan Province, China. Participants were assigned to one of three groups: DTcP-1 (administered at 2, 3, and 4 months), DTcP-2 (administered at 2, 4, and 6 months), or the licensed DTaP-IPV-Hib control (Pentaxim, administered at 2, 3, and 4 months). Safety was monitored over 30 days following the completion of the three-dose primary series, with adverse reactions serving as the primary safety endpoint. Immunogenicity was assessed 30 days after the final dose using a Luminex-based multiplex immunoassay measuring antibody concentrations against pertussis toxoid, filamentous hemagglutinin, pertactin, diphtheria toxoid, and tetanus toxoid.
What Was Observed
- Safety was comparable across all three groups. The overall incidence of adverse reactions after primary vaccination was 14.52% for DTcP-1 and 16.59% for DTcP-2, compared with 16.91% in the DTaP-IPV-Hib group — confirming non-inferiority for both DTcP schedules. No meaningful excess in reactogenicity was observed with the new vaccine.
- Both DTcP schedules met non-inferiority criteria for seroconversion rates and geometric mean concentrations (GMCs) against all pertussis antigens (pertussis toxoid, filamentous hemagglutinin, and pertactin), as well as against diphtheria and tetanus toxoids, compared with the licensed control at 30 days post-primary series.
- Superiority thresholds were also achieved for at least some pertussis antigen responses under one or both DTcP schedules, indicating that the novel three-component formulation elicited stronger humoral responses against key pertussis antigens than the comparator in certain immunological endpoints.
- The extended spacing schedule (DTcP-2: 2/4/6 months) produced immunogenic responses consistent with the compressed schedule (DTcP-1: 2/3/4 months), suggesting scheduling flexibility without apparent loss of immunological benefit across the primary series window.
Why This Matters
Acellular pertussis vaccines have been associated with faster waning immunity compared to whole-cell formulations, contributing to cyclical resurgences even in well-vaccinated populations. The introduction of a domestically engineered three-component vaccine in China addresses both a public health supply concern and the scientific need for broader antigen coverage. Demonstrating superiority on pertussis-specific endpoints against an established benchmarked comparator is a notable immunological result that may inform future vaccine formulation strategies globally.
How to Read This Result
While the immunogenicity and short-term safety data are encouraging, this trial measured antibody responses at 30 days post-primary series only, and longer-term durability data, effectiveness against clinical pertussis disease, and generalisability beyond the Chinese infant population remain to be established.
Limitations
The abstract does not explicitly report study limitations.